|
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Therefore, while under normoxic conditions, EGF stimulates the activation of both the PI3K and the MAPK pathways and the induction of VEGF, in glioblastoma cells, hypoxic conditions lead to the suppression of the PI3K/RhoA/C pathway and an exclusive switch to the MAPK pathway.
|
31698752 |
2019 |
|
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Notch activity in GBM was also shown to be associated with hypoxia and certain cancer-related molecular pathways such as PI3K/AKT/mTOR and ERK/MAPK.
|
31376551 |
2019 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
PI3K and MAPK inhibitors have been studied preclinically in GBM as monotherapy, but not in combination with radiotherapy, which is a key component of the current standard treatment of GBM.
|
28958992 |
2018 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM) development and progression, and in resistance to anti-cancer therapies.
|
31707687 |
2019 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
The tumor suppressor PTEN, a major inhibitor of the phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway, is frequently deleted in GBM tumors.
|
20736378 |
2010 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
We synthesized Gint4.T-conjugated PNPs able of high uptake into U87MG glioblastoma (GBM) cells and with astonishing EC<sub>50</sub> value (38 pM) when loaded with a PI3K-mTOR inhibitor.
|
28471660 |
2017 |
|
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Only one glioblastoma showed both PIK3CA mutation and amplification.
|
17235514 |
2007 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Tivantinib (1 μmol/L) in combination with PI3K inhibitor LY294002 (0.5 μmol/L) and mTOR inhibitor rapamycin (0.1 nmol/L) largely inhibited the proliferation of glioblastoma cells.
|
31575848 |
2019 |
|
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells.
|
28834297 |
2017 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we analyzed the effect of AG1433 (a PDGFR inhibitor), SU1498 (a VEGFR inhibitor) and BEZ235 (a PI3K/Akt/mTOR signaling pathways inhibitor) on glioblastoma cells in vitro.
|
26339347 |
2015 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results show that our in vitro NMR-detected changes in lactate and choline metabolites may have potential as non-invasive biomarkers for monitoring response to combination of PI3K/mTOR inhibitors with TMZ during clinical trials in children with glioblastoma, subject to further in vivo validation.
|
28704425 |
2017 |
|
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Introduction of normal PTEN together with H-Ras(G12V) into U251 glioblastoma cells reduced the PI3K-dependent activation of Akt, but had no effect on vacuolation.
|
17210246 |
2007 |
|
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genomic analyses reveal that signature genetic lesions in GBM and LGG include copy gain and amplification of chromosome 7, amplification, mutation, and overexpression of receptor tyrosine kinases (RTK) such as EGFR, and activating mutations in components of the PI3K pathway.
|
30530503 |
2019 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: These findings provide novel insights into the mechanisms of PI3K inhibitor resistance in glioblastoma.
|
31416846 |
2019 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Serum‑derived hepatitis C virus can infect human glioblastoma cell line SF268 and activate the PI3K‑Akt pathway.
|
30896873 |
2019 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings highlight the important influence in GBM of signaling pathways such as the PI3K/AKT, consistent with the invasive features of this tumor.
|
17002787 |
2006 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis.
|
17616812 |
2007 |
|
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Further, photofrin based PDT followed by miR-99a transfection dramatically increased miR-99a expression and also increased apoptosis in glioblastoma cell cultures and drastically reduced tumor growth in athymic nude mice, due to down regulation of fibroblast growth factor receptor 3 (FGFR3) and PI3K/Akt signaling mechanisms leading to inhibition of cell proliferation and induction of molecular mechanisms of apoptosis.
|
23409016 |
2013 |
|
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Here we show that overexpression of NEU3 in glioblastoma U87MG cells activates PI3K/Akt signaling pathway resulting in an increased radioresistance capacity and in an improved efficiency of double strand DNA-repair mechanisms after irradiation.
|
30466783 |
2019 |
|
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Both pathways are also activated in GBM cell lines, however, only the PI3K pathway seems to play a crucial role in resistance to alkylating agents and might serve as drug target for chemosensitization.
|
29755294 |
2018 |
|
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
GDC-0084 is a brain penetrant, dual PI3K/mTOR inhibitor that has shown promising activity in a preclinical model of glioblastoma.
|
30796030 |
2019 |
|
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The Cancer Genome Atlas integrative analysis of GBM reported the striking finding of genetic alterations in the p53 and PI3K pathways in more than 80% of GBMs.
|
28838997 |
2018 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
This article summarizes recent advances in understanding the role of PI3K catalytic subunits in glioblastoma and discusses the possibility of selective blockade of one PI3K catalytic subunit as a treatment option for glioblastoma.
|
29326882 |
2017 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Locus amplification, gene overexpression, and genetic mutations of epidermal growth factor receptor (EGFR) are hallmarks of GBM that can ectopically activate downstream signaling oncogenic cascades such as PI3K/Akt/mTOR pathway.
|
24691646 |
2014 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this review, we clarify the importance of 4EBP1 as a biomarker for the efficacy of PI3K-AKT-mTOR inhibitors in glioblastoma.
|
28696243 |
2018 |